Pediatric Rheumatology Collaborative Study Group – over four decades of pivotal clinical drug research in pediatric rheumatology

Table 1 Medications studied by the PRCSG Pediatric Rheumatology Collaborative Study Group for Juvenile Idiopathic Arthritis and other pediatric rheumatic diseases by route(s) of administration^a

Medications studied but without approval/licensure by regulatory agencies	Medications studied with approval/licensure by regulatory agencies	Studies in Progress
Oral	Oral	Oral
D-penicillamine	Celecoxib	Baricitinib
Fenoprofen	Ibuprofen	Tofacitinib
Gold	Naproxen	Subcutaneous
Hydroxychloroquine	Rofecoxib^b	Certolizumab pegol
Ketoprofen	Tolmetin	Sarilumab
Meclofenamate	Oral, subcutaneous or intramuscular	Secukinumab
Oxaprozin	Methotrexate	Tocilizumab
Pirprofen	Subcutaneous	Intravenous
Proquazone	Adalimumab	Belimumab^g
Subcutaneous	Canakinumab^c	Golimumab
Anakinra	Etanercept	Rituximab^h
Intravenous	Golimumab^d
Intravenous immunoglobulin	Subcutaneous and/or intravenous
Infliximab	Abatacept^e
Rilonacept	Tocilizumab^f

Biologic medications are printed in Italics
^bApproval withdrawn by the U.S. Food and Drug Administration due to safety concerns in adults with rheumatoid arthritis
^cOnly for systemic juvenile idiopathic arthritis (JIA)
^dApproved by European Medicines Agency only, but not by the U.S. Food and Drug Administration
^eBoth the intravenous and the subcutaneous form is approved for polyarticular JIA
^fThe intravenous forms are approved for systemic JIA and polyarticular JIA
^gFor systemic lupus erythematosus
^hFor antineutrophil cytoplasmic autoantibody (ANCA) associated vasculitis

ISSN: 1546-0096